Abstract: The present disclosure relates to the use of CuPTSM in methods and compositions for treating subjects with a neurodegenerative disease. Subjects with a neurodegenerative disease can have, e.g., amyotrophic lateral sclerosis (ALS).
Type:
Grant
Filed:
July 24, 2020
Date of Patent:
May 30, 2023
Assignee:
ALS THERAPY DEVELOPMENT INSTITUTE
Inventors:
Steven Perrin, Fernando G. Vieira, Alan Gill, Theo Hatzipetros, Kyle Denton, Matvey Lukashev
Abstract: An animal treat composition for the oral administration of a medication to an animal is disclosed. The animal treat composition comprises an adhesive portion core and an outer portion. The adhesive portion adheres to oral medication inserted into the adhesive core of the treat for administration of the medication to an animal.
Abstract: It is an object to provide a therapeutic material for a skin ulcer which has excellent therapeutic effects on intractable skin ulcers such as decubitus ulcers with pockets and huge decubitus ulcers. By applying the therapeutic material for decubitus ulcers consisting of a fibrous material holding an antibiotic and a cell proliferation accelerator therein which is formed into an approximately spherical shape to a site of decubitus in a state in which a defect extending to the dermis, subcutaneous tissue, muscle or bone occurs, it is possible to treat critical skin ulcers such as intractable decubitus ulcers with pockets and huge intractable decubitus ulcers, as well as to treat not only relatively mild decubitus classified as stage II according to the US National Pressure Ulcer Advisory Panel (NPUAP) staging system, i.e.
Abstract: The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.
Type:
Grant
Filed:
October 4, 2019
Date of Patent:
May 16, 2023
Assignee:
Novo Nordisk A/S
Inventors:
Martin Werner Borchsenius Muenzel, Susanne Hostrup, Gro Klitgaard Povlsen, Mathias Norrman, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Peter Madsen
Abstract: A method of preparing a pharmaceutical product comprises the steps of (a) providing a neat active pharmaceutical ingredient (API) complying with at least five of the following parameters determined by using a FT4 powder rheometer: (i) specific basic flow energy of at most 60 mJ/g; (ii) stability index of 0.75 to 1.25; (iii) specific energy of at most 10 mJ/g; (iv) major principle stress at 15 kPa of at most 40; (v) flow function at 15 kPa of at least 1.3; (vi) consolidated bulk density at 15 kPa of at least 0.26 g/mL; (vii) compressibility of at most 47%; and (viii) wall friction angle of at most 40°; (b) dispensing the neat API of step (a) into a bottom part of a pharmaceutical carrier using a vacuum assisted metering and filling device; and (c) encapsulating the bottom part, thereby producing a pharmaceutical product.
Type:
Grant
Filed:
September 28, 2018
Date of Patent:
May 9, 2023
Assignee:
Novartis AG
Inventors:
Elodia Di Renzo, David Hook, Markus Krumme, Steffen Lang, Massimo Moratto, Joerg Ogorka, Jim Parks, Dale Ploeger, Norbert Rasenack, Hendrik Schneider, Stefan Steigmiller, Gordon Stout, Patrick Tritschler, Fabian Weber
Abstract: The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.
Type:
Grant
Filed:
July 9, 2021
Date of Patent:
May 9, 2023
Assignee:
Massachusetts Institute of Technology
Inventors:
Kelly Dare Moynihan, Rebecca Lynn Holden, Darrell J. Irvine, Bradley Lether Pentelute
Abstract: The present invention is generally directed to chemically synthesized peptides that are charged with zinc ions (herein “zinc-charged peptides”). The chemically synthesized peptides are based on the amino acid sequence of alpha-lactalbumin. The present invention is further directed to a method of preparing these two zinc-charged peptides by charging the chemically synthesized peptides with zinc ions. It is observed that charging these peptides with zinc ions activate the peptide's ability to induce apoptosis in cancer cell lines, as well as increase ATP, reduce Tau protein and inhibit P38 in the brain. The zinc-charged peptides are thus capable of treating cancer and diseases involving tauopathy such as Alzheimer's Disease. The present invention is thus further directed to a method of treating cancer and diseases involving tauopathy such as Alzheimer's Disease using the zinc-charged peptides.
Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
Type:
Grant
Filed:
June 7, 2021
Date of Patent:
May 2, 2023
Assignee:
Braintree Laboratories, Inc.
Inventors:
Mark vB Cleveland, Edmund V. Dennett, Jr., Russell W Pelham
Abstract: The disclosure relates to integrin binding peptides, pharmaceutical compositions comprising the peptides and to uses thereof as therapeutic, diagnostic, imaging and targeting agents.
Abstract: The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particular the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH).
Type:
Grant
Filed:
May 3, 2019
Date of Patent:
April 25, 2023
Assignee:
Novo Nordisk A/S
Inventors:
Wouter Frederik Johan Hogendorf, Henning Thoegersen, Nicholas Raymond Cox, Patrick J. Knerr, Richard Dimarchi, Brian Finan, Jesper F. Lau, Steffen Reedtz-Runge, Fa Liu
Abstract: The present invention relates to a family of peptides which are able to interfere in the formation of complex Munc18-Syntaxin-1 and, hence, are useful in the prevention and/or treatment of neuronal exocytosis and/or muscle contractility disorders; and to prevent, reduce and/or eliminate skin aging and/or expression signs.
Type:
Grant
Filed:
February 22, 2019
Date of Patent:
April 25, 2023
Assignee:
LIPOTRUE, S.L.
Inventors:
Ariadna Grau-Campistany, Silvia Pastor, Patricia Carulla, Juan Carlos Escudero, Julia A. Boras, Isabel Devesa Giner, Gregorio Fernandez Ballester
Abstract: Provided herein are alpha-conotoxin peptide analogs, including alpha-conotoxin peptide analogs that are covalently attached to polyethylene glycol (PEG), and pharmaceutical compositions of such alpha-conotoxin peptide analogs. Also provided herein are methods of treating or preventing a condition conducive to treatment or prevention by inhibition of an ?9-containing nicotinic acetylcholine receptor (nAChR) (e.g., the ?9?10 subtype of the nAChR) in a subject.
Type:
Grant
Filed:
January 3, 2020
Date of Patent:
March 28, 2023
Assignee:
Kineta Chronic Pain, LLC
Inventors:
Jose Mercado, Eric J. Tarcha, Jeffrey J. Posakony, Shawn Iadonato
Abstract: Provided are a GLP-1(7-37) polypeptide analogue, a fatty acid-modified derivative of the analogue, and a medicament comprising the derivative. Further, also provided are a preparation method of the derivative, and use of the same in the preparation of a medicament.
Abstract: The present invention relates to new compositions suitable for use in the treatment of articular disorders (or conditions), processes for preparing said compositions and use of said compositions in therapeutic treatments of articular disorders.
Type:
Grant
Filed:
January 26, 2018
Date of Patent:
March 28, 2023
Assignee:
Aboca S.p.A. Società Agricola
Inventors:
Valentino Mercati, Carla Ghelardini, Lorenzo Di Cesare Mannelli
Abstract: Described herein are Notch-modulating peptides (including monomers and multimers) capable of increasing or decreasing an immune response in a subject, compositions comprising the peptides, and methods of use thereof.
Type:
Grant
Filed:
March 26, 2018
Date of Patent:
March 28, 2023
Assignee:
Ohio State Innovation Foundation
Inventors:
Thomas J. Magliery, Mikhail M. Dikov, David Carbone, Nicholas Long, Brandon Sullivan, Elena Tchekneva
Abstract: The present invention relates to effective pain therapies in companion animals. In particular, an isolated companion animal p75NTR protein or a fusion protein containing the same or portions thereof are contemplated. Nucleic acids encoding the proteins are also encompassed in the invention as well as methods of using the same.
Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Type:
Grant
Filed:
October 8, 2021
Date of Patent:
March 14, 2023
Assignee:
Flamel Ireland Limited
Inventors:
Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Type:
Grant
Filed:
October 8, 2021
Date of Patent:
March 14, 2023
Assignee:
Flamel Ireland Limited
Inventors:
Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
Abstract: This invention relates generally to an emollient topical composition of matter that contains molecular iodine with a reduced effective vapor pressure. In specific embodiments, the composition reduces the loss of molecular iodine to the atmosphere under storage conditions after application to mammalian tissue.
Type:
Grant
Filed:
July 19, 2017
Date of Patent:
March 7, 2023
Assignee:
I2PURE CORP.
Inventors:
Jack Kessler, David C. Litzinger, Christopher Rhodes, Andrew M. Cerro